News Allergy Therapeutics suffers phase 3 birch allergy jab trial... UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms.
Views & Analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new... Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face